Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials
Dipeptidyl peptidase 4 (DPP-4) inhibitors are new antidiabetic drugs. Their effects on the respiratory system remain unclear. This study aimed to determine the association between DDP-4 inhibitors and acute respiratory failure (ARF) among patients with type 2 diabetes mellitus (T2DM). A meta-analysi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2024-12-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/12/71_EJ24-0164/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591917097943040 |
|---|---|
| author | Yan Wang Caiyuan Yu Xiaoyan Zheng Yaya Wang Wei Zhang |
| author_facet | Yan Wang Caiyuan Yu Xiaoyan Zheng Yaya Wang Wei Zhang |
| author_sort | Yan Wang |
| collection | DOAJ |
| description | Dipeptidyl peptidase 4 (DPP-4) inhibitors are new antidiabetic drugs. Their effects on the respiratory system remain unclear. This study aimed to determine the association between DDP-4 inhibitors and acute respiratory failure (ARF) among patients with type 2 diabetes mellitus (T2DM). A meta-analysis was performed by searching the PubMed, Embase, and CENTRAL databases up to July 3rd, 2024, to identify randomized controlled, double-blind, and placebo controlled-cardiovascular outcomes trials (CVOTs) that enrolled participants with T2DM. A total of 6,532 studies were initially retrieved; ultimately, 5 large CVOTs enrolling 47,714 adult T2DM patients were included in the meta-analysis. Overall, there were a nonsignificant increase in the risk of ARF in the DDP-4 inhibitor group compared with the placebo group (RR, 1.72; 95% CI, 0.59 to 4.97; p = 0.319). This is the first meta-analysis to evaluate the association between DDP-4 inhibitors and ARF among T2DM patients. In general, these findings suggest that DPP-4 inhibitors may slightly, but non-significantly, increase the risk of ARF in T2DM patients. As few studies are available and few ARF events occurred, further well-designed large-scale studies need to be performed. |
| format | Article |
| id | doaj-art-7eb260d4ef50435397d24c5230182a7a |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-7eb260d4ef50435397d24c5230182a7a2025-01-22T05:34:08ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402024-12-0171121175118110.1507/endocrj.EJ24-0164endocrjEffects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trialsYan Wang0Caiyuan Yu1Xiaoyan Zheng2Yaya Wang3Wei Zhang4College of Agroforestry and Medicine, The Open University of China, Beijing, 100039, People’s Republic of ChinaCollege of Agroforestry and Medicine, The Open University of China, Beijing, 100039, People’s Republic of ChinaCollege of Agroforestry and Medicine, The Open University of China, Beijing, 100039, People’s Republic of ChinaCollege of Agroforestry and Medicine, The Open University of China, Beijing, 100039, People’s Republic of ChinaState Key Laboratory of Quality Research in Chinese Medicines, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, 999078, People’s Republic of ChinaDipeptidyl peptidase 4 (DPP-4) inhibitors are new antidiabetic drugs. Their effects on the respiratory system remain unclear. This study aimed to determine the association between DDP-4 inhibitors and acute respiratory failure (ARF) among patients with type 2 diabetes mellitus (T2DM). A meta-analysis was performed by searching the PubMed, Embase, and CENTRAL databases up to July 3rd, 2024, to identify randomized controlled, double-blind, and placebo controlled-cardiovascular outcomes trials (CVOTs) that enrolled participants with T2DM. A total of 6,532 studies were initially retrieved; ultimately, 5 large CVOTs enrolling 47,714 adult T2DM patients were included in the meta-analysis. Overall, there were a nonsignificant increase in the risk of ARF in the DDP-4 inhibitor group compared with the placebo group (RR, 1.72; 95% CI, 0.59 to 4.97; p = 0.319). This is the first meta-analysis to evaluate the association between DDP-4 inhibitors and ARF among T2DM patients. In general, these findings suggest that DPP-4 inhibitors may slightly, but non-significantly, increase the risk of ARF in T2DM patients. As few studies are available and few ARF events occurred, further well-designed large-scale studies need to be performed.https://www.jstage.jst.go.jp/article/endocrj/71/12/71_EJ24-0164/_html/-char/endipeptidyl peptidase 4 inhibitorsacute respiratory failuretype 2 diabetes mellitusmeta-analysiscardiovascular outcomes trials |
| spellingShingle | Yan Wang Caiyuan Yu Xiaoyan Zheng Yaya Wang Wei Zhang Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials Endocrine Journal dipeptidyl peptidase 4 inhibitors acute respiratory failure type 2 diabetes mellitus meta-analysis cardiovascular outcomes trials |
| title | Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials |
| title_full | Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials |
| title_fullStr | Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials |
| title_full_unstemmed | Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials |
| title_short | Effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcomes trials |
| title_sort | effects of dipeptidyl peptidase 4 inhibitors on the risk of acute respiratory failure in patients with type 2 diabetes mellitus a meta analysis of cardiovascular outcomes trials |
| topic | dipeptidyl peptidase 4 inhibitors acute respiratory failure type 2 diabetes mellitus meta-analysis cardiovascular outcomes trials |
| url | https://www.jstage.jst.go.jp/article/endocrj/71/12/71_EJ24-0164/_html/-char/en |
| work_keys_str_mv | AT yanwang effectsofdipeptidylpeptidase4inhibitorsontheriskofacuterespiratoryfailureinpatientswithtype2diabetesmellitusametaanalysisofcardiovascularoutcomestrials AT caiyuanyu effectsofdipeptidylpeptidase4inhibitorsontheriskofacuterespiratoryfailureinpatientswithtype2diabetesmellitusametaanalysisofcardiovascularoutcomestrials AT xiaoyanzheng effectsofdipeptidylpeptidase4inhibitorsontheriskofacuterespiratoryfailureinpatientswithtype2diabetesmellitusametaanalysisofcardiovascularoutcomestrials AT yayawang effectsofdipeptidylpeptidase4inhibitorsontheriskofacuterespiratoryfailureinpatientswithtype2diabetesmellitusametaanalysisofcardiovascularoutcomestrials AT weizhang effectsofdipeptidylpeptidase4inhibitorsontheriskofacuterespiratoryfailureinpatientswithtype2diabetesmellitusametaanalysisofcardiovascularoutcomestrials |